Select your language
Prof. Jean BOURHISDear colleagues, dear friends,
Clinical research is becoming increasingly complex with more constraints for investigators, stricter regulations, and exponentially growing costs for sponsors. In this context, it is essential to preserve and strengthen our academic research potential, particularly through cooperative oncology groups. In the face of this growing complexity, GORTEC is organizing itself by optimizing its partnership research and its internal processes. A key element for the group's sustainability is our ability to create new collaboration opportunities with industrial partners and to diversify our portfolio, which we are actively doing, among other things, by relying on the newly created Early Assets Board. The second ongoing project is to optimize the implementation of each study, ensuring a perfect match between needs and resources, reducing costs, and especially simplifying everything that can be simplified in the protocol, CRF, monitoring, etc. Supported by our strong and motivated operational team, all of this is currently being implemented through a pilot experience conducted for the upcoming study involving patients in the first-line relapse/metastatic setting (Tatiana study).
Driven by the strong involvement of our investigators and the efficiency of our operational team, GORTEC is more determined than ever to meet the growing challenges posed by clinical research!
Dr Yoann PointreauDear Colleagues, Dear Friends, Dear Everyone,
Gortec has experienced and continues to maintain a strong momentum in its clinical trials over the past few years, some of which are unique, others innovative, and some strategic.
The NIVO-POSTOP study will change practices, with communications planned for 2025.
The biannual meetings of the ENT intergroup provide opportunities to share progress and discuss new projects, with representation from the professions involved in the management of head and neck carcinomas. The group of physicists has regained its rightful place, and the initial work has borne fruit.
The board of directors, whose members are listed just after this message, maintains a strong dynamic and meets at least four times a year:
Gortec encompasses all the internalized poles to conduct our trials, with some of them incubated within the Early Asset Board chaired by Esma Saada.
The Young Gortec, under the aegis of Yasmine El Houat, continues its deployment.
We always count on all investigators and all centers to effectively include participants in all our trials.
A big thank you to everyone.
See you soon !